16-2-6　ⓔ文献

1. Placzkowski KA, Vella A, et al: Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987–2007. J Clin Endocrinol Metab, 2009; 94: 1069–1073.

2. Mehrabi A, Fischer L, et al: A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas, 2014; 43: 675–686.

3. Hirshberg B, Livi A, et al: Forty–eight–hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab, 2000; 85: 3222–3226.

4. Cryer PE, Axelrod L, et al: Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 2009; 94: 709–728.

5. Thakker RV, Newey PJ, et al: Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metabo, 2012; 97: 2990–3011.

6. de Herder WW, van Schaik E, et al: New therapeutic options for metastatic malignant insulinomas. Clin Endocrinol, 2011; 75: 277–284.

7. Kunz PL, Reidy–Lagunes D, et al: Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas, 2013; 42: 557–577.

8. Baratelli C, Brizzi MP, et al: Intermittent everolimus administration for malignant insulinoma. Endocrinol Diabetes Metab Case Rep, 2014; 2014: 140047.

9. Suzuki L, Miyatsuka T, et al: Everolimus directly suppresses insulin secretion independently of cell growth inhibition. J Endocr Soc, 2018; 2: 589–596.